Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lupuzor Phase 3 in SLE
NCT02504645Phase 3Completed
- Sponsor
- ImmuPharma
- Start
- Mar 2015
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of foralumab in systemic lupus erythematosus (SLE) (2 arms), sponsored by ImmuPharma. Primary endpoint: Systemic Lupus Erythematosus Responder Index at 52 weeks. Started Mar 2015; status: completed.
02
Drugs
foralumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02504645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02504645.